CompletedNCT03093064
Natalizumab and Brain Inflammation in Schizophrenia
About this title
Read the official source — NCT03093064Medication studyAges 18–50United Kingdom
Understand this study
Who was this study for?
Listed age limits: 18 years to 50 years.
- Listed locations
- LondonSee all locations and recruitment
- Study phase
- Phase 1Usually an early study focused on safety, tolerability, dosage, and side effects.
Study information
Study start dateStarted: April 1, 2017
- Recruitment status
- Completed
- Enrollment listed in the registry
- 66
- Sponsor
- King's College London
- Sponsor type
- University
- Study type
- Drug
- Intervention type
- Drug, Other
- Study phase
- Phase 1Usually an early study focused on safety, tolerability, dosage, and side effects.
- Locations
- United Kingdom
- Age range
- From 18 Years to 50 Years
- Official registry ID
- NCT03093064
- Official title
Show the full official title
The Role of Inflammation in Brain and Cognitive Function in Mental Disorders
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
London
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is King's College London, a university.
Did this study involve medication?
Yes. The study involved medication, including Natalizumab.
Who was this study for?
Listed age limits: 18 years to 50 years.
